Abemaciclib vs Palbociclib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HR+/HER2- Metastatic Breast Cancer

Shared mechanism: CDK4 and CDK6 · full HR+/HER2- Metastatic Breast Cancer pipeline

Abemaciclib · Verzenio

Marketed by Eli Lilly

Approved in HR+/HER2- Metastatic Breast Cancersmall molecule
Reliable signal

NCT02107703 · Phase 3 · active, not recruiting

This was a randomized, double-blind, placebo-controlled phase 3 trial of 669 women. The primary endpoint, progression-free survival, was met with a clear, statistically significant advantage for abemaciclib plus fulvestrant.

Next expected readout: December 2026 · NCT05305924 (registry estimate)

Reported efficacy

Progression-Free Survival (PFS) (From Date of Randomization until Disease Progression or Death Due to Any Cause (Up To 31 Months)): Progression-Free Survival (PFS) (From Date of Randomization until Disease Progression or Death Due to Any Cause (Up To 31 Months)): Abemaciclib + Fulvestrant 16.4 Months (95% CI 14.4 to 19.3) vs Placebo + Fulvestrant 9.3 Months (95% CI 7.4 to 11.4) (met)

Result source: NCT02107703

Palbociclib · Ibrance

Marketed by Pfizer

Approved in HR+/HER2- Metastatic Breast Cancersmall molecule
Reliable signal

NCT01740427 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled phase 3 trial with 666 participants. Its primary clinical endpoint, investigator-assessed progression-free survival using RECIST criteria, was significantly improved with palbociclib plus letrozole (hazard ratio 0.576; p<0.000001), supporting a strong evidence grade.

Next expected readout: November 2026 · NCT02605486 (registry estimate)

Reported efficacy

Progression-Free Survival (PFS) Based on Investigator's Assessment: Up to Primary Completion Date (Randomization up to 65 months): Progression-Free Survival (PFS) Based on Investigator's Assessment: Up to Primary Completion Date (Randomization up to 65 months): Palbociclib + Letrozole 21.5 Months (95% CI 16.6 to 24.9) vs Placebo + Letrozole 13.9 Months (95% CI 13.7 to 16.6) (met)

Result source: NCT02297438

Results for HR+/HER2- Metastatic Breast Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAbemaciclibPalbociclib
PFS, median16.4 vs 9.3+7.1 vs placebon 446NCT02107703
11 other results
24.8 vs 14.5+10.3 vs placebon 444NCT01740427
20 other results
OS, median45.8 vs 37.3+8.5 vs placebon 446NCT02107703
6 other results
53.9 vs 51.2+2.7 vs placebon 444NCT01740427
14 other results
ORR35.2% vs 16.1%+19.1 vs placebon 446NCT02107703
4 other results
  • 26.3% vs 10% n 38 · Phase 1/2 · primary NCT03280563
  • 19.7% n 132 · Phase 2 · primary NCT02102490
  • 32.9% vs 13.9% 150 mg + 8 mg/kg + 500 mg · n 79 · Phase 2 · secondary NCT02675231
  • 13.9% vs 13.9% 150 mg + 8 mg/kg · n 79 · Phase 2 · secondary NCT02675231
46.4% vs 38.3%+8.1 vs placebon 444NCT01740427
15 other results
Clinical benefit rate72.2% vs 56.1%+16.1 vs placebon 446NCT02107703
8 other results
85.8% vs 71.2%+14.6 vs placebon 444NCT01740427
10 other results

PFS, median

Abemaciclib
16.4 vs 9.3+7.1 vs placebon 446NCT02107703
11 other results
Palbociclib
24.8 vs 14.5+10.3 vs placebon 444NCT01740427
20 other results

OS, median

Abemaciclib
45.8 vs 37.3+8.5 vs placebon 446NCT02107703
6 other results
Palbociclib
53.9 vs 51.2+2.7 vs placebon 444NCT01740427
14 other results

ORR

Abemaciclib
35.2% vs 16.1%+19.1 vs placebon 446NCT02107703
4 other results
  • 26.3% vs 10% n 38 · Phase 1/2 · primary NCT03280563
  • 19.7% n 132 · Phase 2 · primary NCT02102490
  • 32.9% vs 13.9% 150 mg + 8 mg/kg + 500 mg · n 79 · Phase 2 · secondary NCT02675231
  • 13.9% vs 13.9% 150 mg + 8 mg/kg · n 79 · Phase 2 · secondary NCT02675231
Palbociclib
46.4% vs 38.3%+8.1 vs placebon 444NCT01740427
15 other results

Clinical benefit rate

Abemaciclib
72.2% vs 56.1%+16.1 vs placebon 446NCT02107703
8 other results
Palbociclib
85.8% vs 71.2%+14.6 vs placebon 444NCT01740427
10 other results
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
8 other shared endpoints and safety

Coverage. Abemaciclib: 12 of 12 rows · Palbociclib: 12 of 12 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAbemaciclib
Rows use multiple source trials
Palbociclib
Rows use multiple source trials
Clinical Benefit
responder rate · % of participants
No placebo or comparator arm
42.4% (n=132)a,b,c
NCT02102490 · Phase 2
4 other source trials
13% (n=23)
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
26.9% (n=52)
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
26.1% (n=23)
NCT02308020 · Phase 2 · registry result, not featured evidence
9.1% (n=22)
NCT02308020 · Phase 2 · registry result, not featured evidence
64% (n=47)a,b,c
NCT02668666 · Phase 2 · registry result, not featured evidence
1 other source trial
83.3% (n=12)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
Disease Control
responder rate · % of participants
No placebo or comparator arm
67.4% (n=132)d,b,c
NCT02102490 · Phase 2
4 other source trials
40.7% (n=27)
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
51.7% (n=58)
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
39.3% (n=28)
NCT02308020 · Phase 2 · registry result, not featured evidence
26.1% (n=23)
NCT02308020 · Phase 2 · registry result, not featured evidence
85.7% (n=42)125 mg + 2.5 mgd,b,c
NCT01684215 · Phase 2 · registry result, not featured evidence · combination
1 other source trial
65.4% (n=26)
NCT02499146 · Phase 1 · registry result, not featured evidence · combination
Duration of Response
time to event · months
NA vs 25.6 placebo monthse,c
NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
3 other source trials
9.5 vs NA Trastuzumab + Standard of Care Chemotherapy months150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
12.5 vs NA Trastuzumab + Standard of Care Chemotherapy months150 mg + 8 mg/kg + 500 mg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
13.36 vs 13.03 Fulvestrant months
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
20.1 vs 16.7 placebo monthse,c
NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
7 other source trials
10.4 vs 9 Fulvestrant months
NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
22.4 vs 19.4 placebo months
NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
30.3 vs 24.9 placebo months
NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
9.7 vs 11.2 Capecitabine months
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
20.9 vs 11.1 Letrozole months
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
20.2 vs 11.1 Letrozole months
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
20.3 vs 11.1 Letrozole months
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
Duration of Response
time to event · months
No placebo or comparator arm
8.6 monthsa,b,c
NCT02102490 · Phase 2
4 other source trials
11.12 months1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
17.54 months1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
5.78 months1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
4.63 months1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
5.55 months*125mgf,a,b,c
NCT02630693 · Phase 2 · registry result, not featured evidence · converted to months from 169 days as posted
show 1 more dose
4.14 months*100mg
NCT02630693 · Phase 2 · registry result, not featured evidence · converted to months from 126 days as posted
ORR
responder rate · % of participants
No placebo or comparator arm
19.7% (n=132)a,b,c
NCT02102490 · Phase 2
30% (n=47)a,b,c
NCT02668666 · Phase 2 · registry result, not featured evidence
3 other source trials
47.6% (n=42)125 mg + 2.5 mg
NCT01684215 · Phase 2 · registry result, not featured evidence · combination
33.3% (n=12)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
19.2% (n=26)
NCT02499146 · Phase 1 · registry result, not featured evidence · combination
ORR
event count · % of participants
No placebo or comparator arm
60.6% (n=33)*1000 mgf,g,d,c
NCT03099174 · Phase 1 · registry result, not featured evidence · combination · converted to % from 20 Participants as posted
show 3 more doses
19.4% (n=31)*1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination · converted to % from 6 Participants as posted
3.8% (n=26)*1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
6.7% (n=15)*1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
33.3% (n=54)*g,d,c
NCT03007979 · Phase 2 · registry result, not featured evidence · combination · converted to % from 18 Participants as posted
8 other source trials
0% (n=3) @ 24wk*100 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 0 Participants as posted
0% (n=3) @ 24wk*150 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 0 Participants as posted
6.7% (n=15) @ 24wk*150 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 1 Participants as posted
10% (n=10) @ 24wk*300 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 1 Participants as posted
0% (n=16) @ 24wk*50 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 0 Participants as posted
0% (n=6) @ 24wk*75 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 0 Participants as posted
0% (n=3) @ 24wk*75 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 0 Participants as posted
4% (n=75) @ 24wk*50 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 3 Participants as posted
Overall Survival
time to event · months
No placebo or comparator arm
22.32 monthsa,b,c
NCT02102490 · Phase 2
4 other source trials
10.06 months
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
13.38 months
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
7.13 months
NCT02308020 · Phase 2 · registry result, not featured evidence
2.93 months
NCT02308020 · Phase 2 · registry result, not featured evidence
35.61 months*a,b,c
NCT03633331 · Phase 2 · registry result, not featured evidence · combination · converted to months from 1084 days as posted
8 other source trials
20.73 months100mg
NCT02630693 · Phase 2 · registry result, not featured evidence
21.39 months125mg
NCT02630693 · Phase 2 · registry result, not featured evidence
NA months
NCT03530696 · Phase 2 · registry result, not featured evidence
35.1 months
NCT03530696 · Phase 2 · registry result, not featured evidence · combination
37.9 months
NCT03691493 · Phase 2 · registry result, not featured evidence · combination
NA months125 mg + 2.5 mg
NCT01684215 · Phase 2 · registry result, not featured evidence · combination
NA months
NCT02913430 · Phase 1 · registry result, not featured evidence · combination
18.7541 months
NCT02913430 · Phase 1 · registry result, not featured evidence · combination
PFS
time to event · months
No placebo or comparator arm
6 monthsa,b,c
NCT02102490 · Phase 2
8 other source trials
2.07 months
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
4.41 months
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
1.45 months
NCT02308020 · Phase 2 · registry result, not featured evidence
1.22 months
NCT02308020 · Phase 2 · registry result, not featured evidence
13.6 months1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
33.1 months1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
2.1 months1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
NA months1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
29.4 months*a,b,c
NCT03633331 · Phase 2 · registry result, not featured evidence · combination · converted to months from 895 days as posted
11 other source trials
9.33 months100mg
NCT02630693 · Phase 2 · registry result, not featured evidence
11.3 months125mg
NCT02630693 · Phase 2 · registry result, not featured evidence
9.13 months
NCT02668666 · Phase 2 · registry result, not featured evidence
8.3 months
NCT03530696 · Phase 2 · registry result, not featured evidence
16.9 months
NCT03530696 · Phase 2 · registry result, not featured evidence · combination
30.4 months
NCT03691493 · Phase 2 · registry result, not featured evidence · combination
6.53 months100mg
NCT02384239 · Phase 2 · registry result, not featured evidence
9.4 months125mg
NCT02384239 · Phase 2 · registry result, not featured evidence
18.6 months
NCT02499146 · Phase 1 · registry result, not featured evidence · combination
4.131147 months
NCT02913430 · Phase 1 · registry result, not featured evidence · combination
NA months
NCT02913430 · Phase 1 · registry result, not featured evidence · combination
Dropout rate
25.6%h
NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 23 more results
5.3%
NCT02102490 · Phase 2
31.7%Abemaciclib + Fulvestrant
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
21.2%Abemaciclib + NSAI
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
10.1%150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
6.3%150 mg + 8 mg/kg + 500 mg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
16.7%200 mg
NCT03703466 · Phase 2 · registry result, not featured evidence
8.3%200 mg
NCT03703466 · Phase 2 · registry result, not featured evidence
25%200 mg
NCT03703466 · Phase 2 · registry result, not featured evidence
—Part A Abemaciclib: HR+, HER2+ Bre
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
34.5%Part B Abemaciclib: HR+, HER2- Bre
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
33.3%Part C Abemaciclib: Surgical Resec
NCT02308020 · Phase 2 · registry result, not featured evidence
—Part D Abemaciclib: NSCLC
NCT02308020 · Phase 2 · registry result, not featured evidence
17.4%Part E Abemaciclib: Melanoma
NCT02308020 · Phase 2 · registry result, not featured evidence
—Part F: Abemaciclib HR+ Breast Can
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
17.5%
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestonei
NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 55 more results
n/a: no completion milestone
NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
n/a: no completion milestone
NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
69.1%Palbociclib+Letrozole Australia Co
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
34%Palbociclib+Letrozole India Cohort
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
n/a: no completion milestoneCohort 1: Palbociclib Plus Exemest
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestoneCohort 2: Palbociclib Plus Fulvest
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT02600923 · Phase 3 · registry result, not featured evidence · combination
0%
NCT02692755 · Phase 2/3 · registry result, not featured evidence · combination
1.1%
NCT03633331 · Phase 2 · registry result, not featured evidence · combination
87.5%
NCT04224272 · Phase 2 · registry result, not featured evidence · combination
1.1%125mg
NCT02630693 · Phase 2 · registry result, not featured evidence
0%100mg
NCT02630693 · Phase 2 · registry result, not featured evidence
0%
NCT02668666 · Phase 2 · registry result, not featured evidence
1.4%
NCT03644186 · Phase 2 · registry result, not featured evidence · combination
1.8%
NCT03007979 · Phase 2 · registry result, not featured evidence · combination
1.6%
NCT02536742 · Phase 2 · registry result, not featured evidence
12.5%Single Agent T-DM1
NCT03530696 · Phase 2 · registry result, not featured evidence
2.6%T-DM1 With Palbociclib
NCT03530696 · Phase 2 · registry result, not featured evidence · combination
2.8%
NCT03691493 · Phase 2 · registry result, not featured evidence · combination
0%125mg
NCT02384239 · Phase 2 · registry result, not featured evidence
0%100mg
NCT02384239 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone125 mg
NCT01684215 · Phase 2 · registry result, not featured evidence
—125 mg + 2.5 mg
NCT01684215 · Phase 2 · registry result, not featured evidence · combination
—125 mg + 2.5 mg
NCT01684215 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone100 mg
NCT01684215 · Phase 2 · registry result, not featured evidence
—Ph2P1 (Palbociclib + Letrozole)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
—Ph2P2 (Palbociclib + Letrozole)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
100%Phase 1 (Palbociclib + Letrozole)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
97.6%Phase 2 (Palbociclib + Letrozole)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone300 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
n/a: no completion milestone150 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone150 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
n/a: no completion milestone150 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
n/a: no completion milestone100 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone100 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
n/a: no completion milestone75 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
n/a: no completion milestone75 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
n/a: no completion milestone50 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone50 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone50 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
n/a: no completion milestone50 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
n/a: no completion milestone25 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone25 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
—125mg
NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination
—100mg
NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination
—100mg
NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT02499146 · Phase 1 · registry result, not featured evidence · combination
0%Fulvestrant + Palbociclib
NCT02913430 · Phase 1 · registry result, not featured evidence · combination
0%Tamoxifen + Palbociclib
NCT02913430 · Phase 1 · registry result, not featured evidence · combination
—8 mg
NCT03238196 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone8 mg
NCT03238196 · Phase 1 · registry result, not featured evidence · combination
—6 mg
NCT03238196 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone6 mg
NCT03238196 · Phase 1 · registry result, not featured evidence · combination
—5 mg
NCT03238196 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone5 mg
NCT03238196 · Phase 1 · registry result, not featured evidence · combination
Discontinued due to AEs
—h
NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 23 more results
—
NCT02102490 · Phase 2
3.2%Abemaciclib + Fulvestrant
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
1.5%Abemaciclib + NSAI
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
—150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
—150 mg + 8 mg/kg + 500 mg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
—200 mg
NCT03703466 · Phase 2 · registry result, not featured evidence
—200 mg
NCT03703466 · Phase 2 · registry result, not featured evidence
—200 mg
NCT03703466 · Phase 2 · registry result, not featured evidence
—Part A Abemaciclib: HR+, HER2+ Bre
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
—Part B Abemaciclib: HR+, HER2- Bre
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
—Part C Abemaciclib: Surgical Resec
NCT02308020 · Phase 2 · registry result, not featured evidence
—Part D Abemaciclib: NSCLC
NCT02308020 · Phase 2 · registry result, not featured evidence
—Part E Abemaciclib: Melanoma
NCT02308020 · Phase 2 · registry result, not featured evidence
—Part F: Abemaciclib HR+ Breast Can
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
—
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
0%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
14.3%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
14.3%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
18.2%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
12.9%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
25%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
19.2%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
20%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
7.2%i
NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 55 more results
8.9%
NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
—
NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
3.9%Palbociclib+Letrozole Australia Co
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
2%Palbociclib+Letrozole India Cohort
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
5.2%Cohort 1: Palbociclib Plus Exemest
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
2%Cohort 2: Palbociclib Plus Fulvest
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
2.3%
NCT02600923 · Phase 3 · registry result, not featured evidence · combination
—
NCT02692755 · Phase 2/3 · registry result, not featured evidence · combination
—
NCT03633331 · Phase 2 · registry result, not featured evidence · combination
—
NCT04224272 · Phase 2 · registry result, not featured evidence · combination
—125mg
NCT02630693 · Phase 2 · registry result, not featured evidence
—100mg
NCT02630693 · Phase 2 · registry result, not featured evidence
—
NCT02668666 · Phase 2 · registry result, not featured evidence
—
NCT03644186 · Phase 2 · registry result, not featured evidence · combination
—
NCT03007979 · Phase 2 · registry result, not featured evidence · combination
—
NCT02536742 · Phase 2 · registry result, not featured evidence
—Single Agent T-DM1
NCT03530696 · Phase 2 · registry result, not featured evidence
—T-DM1 With Palbociclib
NCT03530696 · Phase 2 · registry result, not featured evidence · combination
—
NCT03691493 · Phase 2 · registry result, not featured evidence · combination
—125mg
NCT02384239 · Phase 2 · registry result, not featured evidence
—100mg
NCT02384239 · Phase 2 · registry result, not featured evidence
0%125 mg
NCT01684215 · Phase 2 · registry result, not featured evidence
—125 mg + 2.5 mg
NCT01684215 · Phase 2 · registry result, not featured evidence · combination
—125 mg + 2.5 mg
NCT01684215 · Phase 2 · registry result, not featured evidence · combination
16.7%100 mg
NCT01684215 · Phase 2 · registry result, not featured evidence
—Ph2P1 (Palbociclib + Letrozole)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
—Ph2P2 (Palbociclib + Letrozole)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
0%Phase 1 (Palbociclib + Letrozole)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
15.5%Phase 2 (Palbociclib + Letrozole)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
—300 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
—150 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
—150 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
—150 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
—100 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
—100 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
—75 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
—75 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
—50 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
—50 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
—50 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
—50 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
—25 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
—25 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
—125mg
NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination
—100mg
NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination
—100mg
NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination
11.5%
NCT02499146 · Phase 1 · registry result, not featured evidence · combination
—Fulvestrant + Palbociclib
NCT02913430 · Phase 1 · registry result, not featured evidence · combination
—Tamoxifen + Palbociclib
NCT02913430 · Phase 1 · registry result, not featured evidence · combination
—8 mg
NCT03238196 · Phase 1 · registry result, not featured evidence · combination
50%8 mg
NCT03238196 · Phase 1 · registry result, not featured evidence · combination
—6 mg
NCT03238196 · Phase 1 · registry result, not featured evidence · combination
33.3%6 mg
NCT03238196 · Phase 1 · registry result, not featured evidence · combination
—5 mg
NCT03238196 · Phase 1 · registry result, not featured evidence · combination
0%5 mg
NCT03238196 · Phase 1 · registry result, not featured evidence · combination
Serious AEs
29.3%h
NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 23 more results
25%
NCT02102490 · Phase 2
7.9%Abemaciclib + Fulvestrant
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
6.6%Abemaciclib + NSAI
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
19.5%150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
30.8%150 mg + 8 mg/kg + 500 mg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
12.5%200 mg
NCT03703466 · Phase 2 · registry result, not featured evidence
33.3%200 mg
NCT03703466 · Phase 2 · registry result, not featured evidence
21.7%200 mg
NCT03703466 · Phase 2 · registry result, not featured evidence
22.2%Part A Abemaciclib: HR+, HER2+ Bre
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
27.6%Part B Abemaciclib: HR+, HER2- Bre
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
33.3%Part C Abemaciclib: Surgical Resec
NCT02308020 · Phase 2 · registry result, not featured evidence
28.6%Part D Abemaciclib: NSCLC
NCT02308020 · Phase 2 · registry result, not featured evidence
17.4%Part E Abemaciclib: Melanoma
NCT02308020 · Phase 2 · registry result, not featured evidence
41.2%Part F: Abemaciclib HR+ Breast Can
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
35.9%
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
0%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
57.1%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
57.1%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
33.3%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
51.6%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
37.5%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
50%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
26.7%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
28.2%i
NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 55 more results
22.6%
NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
20.2%
NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
29.6%Palbociclib+Letrozole Australia Co
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
18%Palbociclib+Letrozole India Cohort
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
22.7%Cohort 1: Palbociclib Plus Exemest
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
14.1%Cohort 2: Palbociclib Plus Fulvest
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
24.6%
NCT02600923 · Phase 3 · registry result, not featured evidence · combination
—
NCT02692755 · Phase 2/3 · registry result, not featured evidence · combination
38%
NCT03633331 · Phase 2 · registry result, not featured evidence · combination
15.7%
NCT04224272 · Phase 2 · registry result, not featured evidence · combination
13.5%125mg
NCT02630693 · Phase 2 · registry result, not featured evidence
10%100mg
NCT02630693 · Phase 2 · registry result, not featured evidence
32.7%
NCT02668666 · Phase 2 · registry result, not featured evidence
54.2%
NCT03644186 · Phase 2 · registry result, not featured evidence · combination
27.8%
NCT03007979 · Phase 2 · registry result, not featured evidence · combination
73%
NCT02536742 · Phase 2 · registry result, not featured evidence
21.4%Single Agent T-DM1
NCT03530696 · Phase 2 · registry result, not featured evidence
21.1%T-DM1 With Palbociclib
NCT03530696 · Phase 2 · registry result, not featured evidence · combination
—
NCT03691493 · Phase 2 · registry result, not featured evidence · combination
5.9%125mg
NCT02384239 · Phase 2 · registry result, not featured evidence
13.9%100mg
NCT02384239 · Phase 2 · registry result, not featured evidence
0%125 mg
NCT01684215 · Phase 2 · registry result, not featured evidence
9.5%125 mg + 2.5 mg
NCT01684215 · Phase 2 · registry result, not featured evidence · combination
33.3%125 mg + 2.5 mg
NCT01684215 · Phase 2 · registry result, not featured evidence · combination
0%100 mg
NCT01684215 · Phase 2 · registry result, not featured evidence
30.3%Ph2P1 (Palbociclib + Letrozole)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
24%Ph2P2 (Palbociclib + Letrozole)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
16.7%Phase 1 (Palbociclib + Letrozole)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
26.5%Phase 2 (Palbociclib + Letrozole)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
20%300 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
33.3%150 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
0%150 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
13.3%150 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
16.7%100 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
33.3%100 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
16.7%75 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
0%75 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
0%50 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
11.1%50 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
0%50 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
12%50 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
20%25 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
40%25 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
100%125mg
NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination
83.3%100mg
NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination
87.5%100mg
NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination
15.4%
NCT02499146 · Phase 1 · registry result, not featured evidence · combination
40%Fulvestrant + Palbociclib
NCT02913430 · Phase 1 · registry result, not featured evidence · combination
0%Tamoxifen + Palbociclib
NCT02913430 · Phase 1 · registry result, not featured evidence · combination
25%8 mg
NCT03238196 · Phase 1 · registry result, not featured evidence · combination
—8 mg
NCT03238196 · Phase 1 · registry result, not featured evidence · combination
16.7%6 mg
NCT03238196 · Phase 1 · registry result, not featured evidence · combination
—6 mg
NCT03238196 · Phase 1 · registry result, not featured evidence · combination
33.3%5 mg
NCT03238196 · Phase 1 · registry result, not featured evidence · combination
—5 mg
NCT03238196 · Phase 1 · registry result, not featured evidence · combination
Most frequent reported AEs
h
diarrhoea 87.1% (placebo 27.8%)
neutropenia 49.7% (placebo 3.6%)
nausea 49.4% (placebo 24.7%)
NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 23 more results
diarrhoea 90.9%
nausea 67.4%
fatigue 47.7%
NCT02102490 · Phase 2
diarrhoea 28.6%
anaemia 22.2%
fatigue 20.6%
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
diarrhoea 29.9%
neutropenia 24.8%
anaemia 23.4%
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
150 mg + 8 mg/kg
diarrhoea 77.9%
fatigue 53.2%
nausea 41.6%
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
150 mg + 8 mg/kg + 500 mg
diarrhoea 79.5%
fatigue 57.7%
nausea 48.7%
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
200 mg
diarrhoea 87.5%
nausea 62.5%
anaemia 58.3%
NCT03703466 · Phase 2 · registry result, not featured evidence
200 mg
diarrhoea 91.7%
nausea 58.3%
anaemia 41.7%
NCT03703466 · Phase 2 · registry result, not featured evidence
200 mg
diarrhoea 95.7%
anaemia 47.8%
nausea 47.8%
NCT03703466 · Phase 2 · registry result, not featured evidence
diarrhoea 55.6%
fatigue 33.3%
nausea 33.3%
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
diarrhoea 77.6%
fatigue 48.3%
nausea 44.8%
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
alanine aminotransferase increased 66.7%
anaemia 44.4%
diarrhoea 44.4%
NCT02308020 · Phase 2 · registry result, not featured evidence
diarrhoea 53.6%
fatigue 39.3%
nausea 28.6%
NCT02308020 · Phase 2 · registry result, not featured evidence
abdominal pain 21.7%
diarrhoea 21.7%
neutropenia 21.7%
NCT02308020 · Phase 2 · registry result, not featured evidence
fatigue 52.9%
nausea 41.2%
diarrhoea 35.3%
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
diarrhoea 84.6%
fatigue 43.6%
nausea 43.6%
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
1000 mg
diarrhoea 100%
decreased appetite 66.7%
vomiting 66.7%
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
1000 mg
anaemia 100%
diarrhoea 100%
aspartate aminotransferase increased 85.7%
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
1000 mg
diarrhoea 85.7%
asthenia 71.4%
neutropenia 71.4%
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
1000 mg
diarrhoea 90.9%
nausea 66.7%
neutrophil count decreased 51.5%
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
1000 mg
diarrhoea 93.5%
nausea 67.7%
neutrophil count decreased 51.6%
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
1000 mg
diarrhoea 100%
nausea 75%
asthenia 62.5%
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
1000 mg
diarrhoea 61.5%
nausea 61.5%
decreased appetite 42.3%
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
1000 mg
diarrhoea 93.3%
asthenia 60%
headache 53.3%
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
i
neutropenia 69.4% (placebo 3.6%)
arthralgia 42.1% (placebo 40.1%)
fatigue 41.2% (placebo 29.3%)
NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 49 more results
neutropenia 67%
fatigue 43.8%
nausea 36.5%
NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
neutrophil count decreased 66.7% (placebo 11.1%)
white blood cell count decreased 64.3% (placebo 9.9%)
neutropenia 44.6% (placebo 7%)
NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
neutropenia 72.4%
fatigue 65.1%
nausea 37.5%
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
neutropenia 57%
anaemia 22%
alopecia 17%
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
neutrophil count decreased 62.7%
fatigue 55.3%
hypertension 34%
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
neutrophil count decreased 63.1%
fatigue 51%
hypertension 36.9%
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
neutropenia 70%
leukopenia 34.6%
anaemia 33.8%
NCT02600923 · Phase 3 · registry result, not featured evidence · combination
neutrophil count decreased 92.4%
white blood cell decreased 87%
fatigue 84.8%
NCT03633331 · Phase 2 · registry result, not featured evidence · combination
diarrhoea 92.2%
nausea 52.9%
stomatitis 41.2%
NCT04224272 · Phase 2 · registry result, not featured evidence · combination
125mg
fatigue 82%
nausea 53.9%
back pain 46.1%
NCT02630693 · Phase 2 · registry result, not featured evidence
100mg
fatigue 85.6%
nausea 52.2%
insomnia 48.9%
NCT02630693 · Phase 2 · registry result, not featured evidence
neutrophil count decreased 71.4%
fatigue 65.3%
white blood cell decreased 65.3%
NCT02668666 · Phase 2 · registry result, not featured evidence
diarrhea 65.3%
anemia 48.6%
platelet count decreased 38.9%
NCT03644186 · Phase 2 · registry result, not featured evidence · combination
white blood cell count decreased 96.3%
neutrophil count decreased 87%
anemia 79.6%
NCT03007979 · Phase 2 · registry result, not featured evidence · combination
nausea 57.1%
aspartate aminotransferase increased 50%
fatigue 50%
NCT03530696 · Phase 2 · registry result, not featured evidence
neutrophil count decreased 84.2%
platelet count decreased 76.3%
white blood cell count decreased 76.3%
NCT03530696 · Phase 2 · registry result, not featured evidence · combination
125mg
neutrophil count decreased 26.5%
hypertension 0%
NCT02384239 · Phase 2 · registry result, not featured evidence
100mg
neutrophil count decreased 13.9%
hypertension 5.6%
NCT02384239 · Phase 2 · registry result, not featured evidence
125 mg
white blood cell count decreased 83.3%
diarrhoea 66.7%
neutrophil count decreased 66.7%
NCT01684215 · Phase 2 · registry result, not featured evidence
125 mg + 2.5 mg
neutrophil count decreased 81%
stomatitis 76.2%
white blood cell count decreased 71.4%
NCT01684215 · Phase 2 · registry result, not featured evidence · combination
125 mg + 2.5 mg
neutrophil count decreased 100%
white blood cell count decreased 100%
diarrhoea 66.7%
NCT01684215 · Phase 2 · registry result, not featured evidence · combination
100 mg
neutrophil count decreased 83.3%
white blood cell count decreased 66.7%
aspartate aminotransferase increased 33.3%
NCT01684215 · Phase 2 · registry result, not featured evidence
neutropenia 78.8%
leukopenia 48.5%
fatigue 42.4%
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
neutropenia 72%
fatigue 40%
leukopenia 40%
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
neutropenia 91.7%
fatigue 83.3%
leukopenia 66.7%
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
neutropenia 74.7%
leukopenia 43.4%
fatigue 41%
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
300 mg QD
nausea 40%
fatigue 30%
headache 30%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
150 mg QD
neutrophil count decreased 100%
anaemia 66.7%
fatigue 66.7%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
150 mg BID
abdominal pain 66.7%
ggt increased 66.7%
nausea 66.7%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
150 mg QD
nausea 40%
headache 26.7%
hypertension 26.7%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
100 mg QD
white blood cell count decreased 91.7%
neutrophil count decreased 58.3%
anaemia 41.7%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
100 mg QD
abdominal pain upper 33.3%
arthralgia 33.3%
back pain 33.3%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
75 mg BID
arthralgia 33.3%
fall 33.3%
fatigue 33.3%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
75 mg QD
hypophosphataemia 66.7%
blood alkaline phosphatase increased 33.3%
breast pain 33.3%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
50 mg BID
alt increased 50%
anaemia 50%
cough 50%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
50 mg QD
neutrophil count decreased 77.8%
white blood cell count decreased 77.8%
anaemia 66.7%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
50 mg QD
fatigue 25%
ggt increased 18.8%
arthralgia 12.5%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
50 mg QD
ggt increased 14.7%
covid-19 10.7%
ast increased 9.3%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
25 mg BID
nausea 60%
neutrophil count decreased 60%
white blood cell count decreased 60%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
25 mg QD
neutrophil count decreased 80%
white blood cell count decreased 70%
anaemia 50%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
125mg
mucositis oral 100%
neutrophil count decreased 100%
platelet count decreased 100%
NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination
100mg
mucositis oral 100%
neutrophil count decreased 83.3%
fatigue 50%
NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination
100mg
mucositis oral 96.9%
neutrophil count decreased 87.5%
fatigue 65.6%
NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination
neutrophil count decreased 61.5%
platelet count decreased 57.7%
white blood cell count decreased 57.7%
NCT02499146 · Phase 1 · registry result, not featured evidence · combination
dyspnea 60%
neutrophil count decreased 60%
skin and subcutaneous tissue disorders - other 60%
NCT02913430 · Phase 1 · registry result, not featured evidence · combination
blood and lymphatic system disorders - other 50%
hypertension 50%
neutrophil count decreased 50%
NCT02913430 · Phase 1 · registry result, not featured evidence · combination
8 mg
diarrhea 75%
oral mucositis 75%
dry skin 50%
NCT03238196 · Phase 1 · registry result, not featured evidence · combination
6 mg
fatigue 83.3%
oral mucositis 83.3%
dry mouth 66.7%
NCT03238196 · Phase 1 · registry result, not featured evidence · combination
5 mg
anemia 100%
constipation 100%
dry skin 100%
NCT03238196 · Phase 1 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for both studies.
  2. bTreatment context has not been resolved for both arms.
  3. cThe assessment timepoint is not available for both results.
  4. dPopulation context differs: registered conditions differ.
  5. ePopulation context differs: prior_therapy differs (unrestricted versus naive).
  6. fThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  7. gTrial phases differ: Phase 1 versus Phase 2.
  8. hPopulation comparability has not been reviewed for 23 of these studies.
  9. iPopulation comparability has not been reviewed for 53 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Abemaciclib

Disease Control 78.5% (n=79) vs 67.1% (n=79) Trastuzumab + Standard of Care Chemotherapy150 mg + 8 mg/kg + 500 mg
responder rate · % of participants
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
show 2 more results
74.7% (n=79) vs 67.1% (n=79) Trastuzumab + Standard of Care Chemotherapy150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
83% (n=446) vs 75.8% (n=223) placebo
NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Overall Survival Rate at 12 77.2% (n=79) vs 69.8% (n=79) Trastuzumab + Standard of Care Chemotherapy @ 52wk150 mg + 8 mg/kg + 500 mg
responder rate · % of participants
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
77.4% (n=79) vs 69.8% (n=79) Trastuzumab + Standard of Care Chemotherapy @ 52wk150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
OS Rate at 12 55.8% (n=79) vs 43% (n=79) Trastuzumab + Standard of Care Chemotherapy @ 104wk150 mg + 8 mg/kg + 500 mg
responder rate · % of participants
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
55.7% (n=79) vs 43% (n=79) Trastuzumab + Standard of Care Chemotherapy @ 104wk150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
OS 36mo 46.7% (n=79) vs 29.9% (n=79) Trastuzumab + Standard of Care Chemotherapy @ 156wk150 mg + 8 mg/kg + 500 mg
responder rate · % of participants
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
40.2% (n=79) vs 29.9% (n=79) Trastuzumab + Standard of Care Chemotherapy @ 156wk150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
BPI Total Pain 0 vs 0.31 Trastuzumab + Standard of Care Chemotherapy score150 mg + 8 mg/kg + 500 mg
absolute change · score
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
0.2 vs 0.31 Trastuzumab + Standard of Care Chemotherapy score150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
EORTC QLQ-C30 Global Health Status -2.9 vs -1.9 Trastuzumab + Standard of Care Chemotherapy score150 mg + 8 mg/kg + 500 mg
absolute change · score
Global health status
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
-5.9 vs -1.9 Trastuzumab + Standard of Care Chemotherapy score150 mg + 8 mg/kg
Global health status
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
EORTC QLQ-C30 Physical Functioning -1 vs -4.5 Trastuzumab + Standard of Care Chemotherapy score150 mg + 8 mg/kg + 500 mg
absolute change · score
Functional scale: Physical functioning
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
-4.4 vs -4.5 Trastuzumab + Standard of Care Chemotherapy score150 mg + 8 mg/kg
Functional scale: Physical functioning
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
EORTC QLQ-C30 Role Functioning -2.7 vs -8.2 Trastuzumab + Standard of Care Chemotherapy score150 mg + 8 mg/kg + 500 mg
absolute change · score
Functional scale: Role functioning
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
-5 vs -8.2 Trastuzumab + Standard of Care Chemotherapy score150 mg + 8 mg/kg
Functional scale: Role functioning
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
EORTC QLQ-C30 Emotional Functioning 2.4 vs 1.1 Trastuzumab + Standard of Care Chemotherapy score150 mg + 8 mg/kg + 500 mg
absolute change · score
Functional scale: Emotional functioning
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
-0.4 vs 1.1 Trastuzumab + Standard of Care Chemotherapy score150 mg + 8 mg/kg
Functional scale: Emotional functioning
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
EORTC QLQ-C30 Cognitive Functioning -1.8 vs -1.6 Trastuzumab + Standard of Care Chemotherapy score150 mg + 8 mg/kg + 500 mg
absolute change · score
Functional scale: Cognitive functioning
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
-1.1 vs -1.6 Trastuzumab + Standard of Care Chemotherapy score150 mg + 8 mg/kg
Functional scale: Cognitive functioning
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
EORTC QLQ-C30 Social Functioning -0.9 vs -2.4 Trastuzumab + Standard of Care Chemotherapy score150 mg + 8 mg/kg + 500 mg
absolute change · score
Functional scale: Social functioning
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
-0.9 vs -2.4 Trastuzumab + Standard of Care Chemotherapy score150 mg + 8 mg/kg
Functional scale: Social functioning
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
EORTC QLQ-C30 Fatigue 1.8 vs 4.7 Trastuzumab + Standard of Care Chemotherapy score150 mg + 8 mg/kg + 500 mg
absolute change · score
Symptom scale: Fatigue
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
7 vs 4.7 Trastuzumab + Standard of Care Chemotherapy score150 mg + 8 mg/kg
Symptom scale: Fatigue
NCT02675231 · Phase 2 · registry result, not featured evidence · combination

+ 19 further endpoints in the CSV export.

Palbociclib

Complete 1% (n=100)
responder rate · % of participants
No placebo or comparator arm
Percentage of participants with complete response
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
1.3% (n=152)
Percentage of participants with complete response
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
Partial 28% (n=100)
responder rate · % of participants
No placebo or comparator arm
Percentage of participants with partial response
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
11.8% (n=152)
Percentage of participants with partial response
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
ORR 29% (n=100)
absolute value · percentage points
No placebo or comparator arm
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
show 3 more results
13.2% (n=152)
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
24.8% (n=129)
NCT02600923 · Phase 3 · registry result, not featured evidence · combination
55% (n=47)
NCT03633331 · Phase 2 · registry result, not featured evidence · combination
EQ-5D Utility 0.698 score
absolute value · score
No placebo or comparator arm
End of Treatment (EOT)
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
EQ-5D Utility -0.147 score
absolute change · score
No placebo or comparator arm
End of Treatment (EOT)
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
EQ-5D-VAS 73.6 score
absolute value · score
No placebo or comparator arm
End of Treatment (EOT)
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
EQ-5D VAS -3.2 score
absolute change · score
No placebo or comparator arm
End of Treatment (EOT)
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
ORR 22.8% (n=206) vs 29.4% (n=187) Capecitabine
event count · % of participants
NCT02028507 · Phase 3 · registry result, not featured evidence · combination · converted to % from 47 Participants as posted
Clinical Benefit 76.2% (n=206) vs 82.4% (n=187) Capecitabine
event count · % of participants
NCT02028507 · Phase 3 · registry result, not featured evidence · combination · converted to % from 157 Participants as posted
EORTC QLQ-C30 Global Health Status 3.28 vs 1.97 Capecitabine score
absolute change · score
Global health status / QoL
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
EORTC QLQ-C30 Physical Functioning -1.73 vs -2.94 Capecitabine score
absolute change · score
Physical functioning
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
EORTC QLQ-C30 Role Functioning -1.09 vs -4.97 Capecitabine score
absolute change · score
Role functioning
NCT02028507 · Phase 3 · registry result, not featured evidence · combination

+ 65 further endpoints in the CSV export.

Breast Cancer

Shared mechanism: CDK4 and CDK6 · full Breast Cancer pipeline

Abemaciclib · Verzenio

Marketed by Eli Lilly

Approved in Breast Cancersmall molecule
Reliable signal

NCT02107703 · Phase 3 · active, not recruiting

This was a randomized, double-blind, placebo-controlled phase 3 trial of 669 women. The primary endpoint, progression-free survival, was met with a clear, statistically significant advantage for abemaciclib plus fulvestrant.

Next expected readout: December 2026 · NCT05305924 (registry estimate)

Reported efficacy

Progression-Free Survival (PFS) (From Date of Randomization until Disease Progression or Death Due to Any Cause (Up To 31 Months)): Progression-Free Survival (PFS) (From Date of Randomization until Disease Progression or Death Due to Any Cause (Up To 31 Months)): Abemaciclib + Fulvestrant 16.4 Months (95% CI 14.4 to 19.3) vs Placebo + Fulvestrant 9.3 Months (95% CI 7.4 to 11.4) (met)

Result source: NCT02107703

Palbociclib · Ibrance

Marketed by Pfizer

Approved in Breast Cancersmall molecule
Reliable signal

NCT01740427 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled phase 3 trial with 666 participants. Its primary clinical endpoint, investigator-assessed progression-free survival using RECIST criteria, was significantly improved with palbociclib plus letrozole (hazard ratio 0.576; p<0.000001), supporting a strong evidence grade.

Next expected readout: November 2026 · NCT02605486 (registry estimate)

Reported efficacy

Progression-Free Survival (PFS) Based on Investigator's Assessment: Up to Primary Completion Date (Randomization up to 65 months): Progression-Free Survival (PFS) Based on Investigator's Assessment: Up to Primary Completion Date (Randomization up to 65 months): Palbociclib + Letrozole 21.5 Months (95% CI 16.6 to 24.9) vs Placebo + Letrozole 13.9 Months (95% CI 13.7 to 16.6) (met)

Result source: NCT02297438

Results for Breast Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Coverage. Abemaciclib: 25 of 25 rows · Palbociclib: 25 of 25 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAbemaciclib
Rows use multiple source trials
Palbociclib
Rows use multiple source trials
Clinical Benefit
responder rate · % of participants
72.2% (n=446) vs 56.1% (n=223) placeboa,b
NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
3 other source trials
45.6% (n=79) vs 38% (n=79) Trastuzumab + Standard of Care Chemotherapy150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
58.2% (n=79) vs 38% (n=79) Trastuzumab + Standard of Care Chemotherapy150 mg + 8 mg/kg + 500 mg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
42.1% (n=38) vs 15% (n=20) Fulvestrant
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
85.8% (n=444) vs 71.2% (n=222) placeboa,b
NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
8 other source trials
66.3% (n=347) vs 39.7% (n=174) Fulvestrant
NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
79.3% (n=169) vs 80.1% (n=171) placebo
NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
77.9% (n=145) vs 79.6% (n=142) placebo
NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
76.9% (n=169) vs 73.1% (n=171) placebo
NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
78.1% (n=128) vs 71.8% (n=131) placebo
NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
76.5% (n=34) vs 58% (n=81) Letrozole
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
84% (n=50) vs 58% (n=81) Letrozole
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
81% (n=84) vs 58% (n=81) Letrozole
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
Clinical Benefit
responder rate · % of participants
No placebo or comparator arm
42.4% (n=132)c,d,b
NCT02102490 · Phase 2
4 other source trials
13% (n=23)
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
26.9% (n=52)
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
26.1% (n=23)
NCT02308020 · Phase 2 · registry result, not featured evidence
9.1% (n=22)
NCT02308020 · Phase 2 · registry result, not featured evidence
64% (n=47)c,d,b
NCT02668666 · Phase 2 · registry result, not featured evidence
1 other source trial
83.3% (n=12)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
Disease Control
responder rate · % of participants
No placebo or comparator arm
67.4% (n=132)e,d,b
NCT02102490 · Phase 2
4 other source trials
40.7% (n=27)
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
51.7% (n=58)
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
39.3% (n=28)
NCT02308020 · Phase 2 · registry result, not featured evidence
26.1% (n=23)
NCT02308020 · Phase 2 · registry result, not featured evidence
85.7% (n=42)125 mg + 2.5 mge,d,b
NCT01684215 · Phase 2 · registry result, not featured evidence · combination
Duration of Response
time to event · months
NA vs 25.6 placebo monthsa,b
NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
3 other source trials
9.5 vs NA Trastuzumab + Standard of Care Chemotherapy months150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
12.5 vs NA Trastuzumab + Standard of Care Chemotherapy months150 mg + 8 mg/kg + 500 mg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
13.36 vs 13.03 Fulvestrant months
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
20.1 vs 16.7 placebo monthsa,b
NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
7 other source trials
10.4 vs 9 Fulvestrant months
NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
22.4 vs 19.4 placebo months
NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
30.3 vs 24.9 placebo months
NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
9.7 vs 11.2 Capecitabine months
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
20.9 vs 11.1 Letrozole months
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
20.2 vs 11.1 Letrozole months
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
20.3 vs 11.1 Letrozole months
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
Duration of Response
time to event · months
No placebo or comparator arm
8.6 monthsc,d,b
NCT02102490 · Phase 2
4 other source trials
11.12 months1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
17.54 months1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
5.78 months1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
4.63 months1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
5.55 months*125mgf,c,d,b
NCT02630693 · Phase 2 · registry result, not featured evidence · converted to months from 169 days as posted
show 1 more dose
4.14 months*100mg
NCT02630693 · Phase 2 · registry result, not featured evidence · converted to months from 126 days as posted
EORTC QLQ-C30 Appetite Loss
absolute change · score
Appetite Loss
16.9 vs 1.9 Anastrozole score @ 2wkf,g,e,b
NCT02441946 · Phase 2 · registry result, not featured evidence
show 1 more dose
16.9 vs 1.9 Anastrozole score @ 2wk
NCT02441946 · Phase 2 · registry result, not featured evidence · combination
2.99 vs 1.04 Capecitabine scoreg,e,b
Appetite loss
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
EORTC QLQ-C30 Constipation
absolute change · score
Constipation
16.9 vs 1.9 Anastrozole score @ 2wkf,g,e,b
NCT02441946 · Phase 2 · registry result, not featured evidence
show 1 more dose
22.4 vs 1.9 Anastrozole score @ 2wk
NCT02441946 · Phase 2 · registry result, not featured evidence · combination
3.91 vs -1.45 Capecitabine scoreg,e,b
Constipation
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
EORTC QLQ-C30 Fatigue
absolute change · score
Fatigue
13.9 vs 4 Anastrozole score @ 2wkf,g,e,b
NCT02441946 · Phase 2 · registry result, not featured evidence
show 1 more dose
13.6 vs 4 Anastrozole score @ 2wk
NCT02441946 · Phase 2 · registry result, not featured evidence · combination
3.85 vs 5.79 Capecitabine scoreg,e,b
Fatigue
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
EORTC QLQ-C30 Insomnia
absolute change · score
Insomnia
0.5 vs -1.9 Anastrozole score @ 2wkf,g,e,b
NCT02441946 · Phase 2 · registry result, not featured evidence
show 1 more dose
-1.1 vs -1.9 Anastrozole score @ 2wk
NCT02441946 · Phase 2 · registry result, not featured evidence · combination
-3.04 vs -5.94 Capecitabine scoreg,e,b
Insomnia
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
EORTC QLQ-C30 Pain
absolute change · score
Pain
3.5 vs 2.9 Anastrozole score @ 2wkf,g,e,b
NCT02441946 · Phase 2 · registry result, not featured evidence
show 1 more dose
4.8 vs 2.9 Anastrozole score @ 2wk
NCT02441946 · Phase 2 · registry result, not featured evidence · combination
-1.79 vs -1.9 Capecitabine scoreg,e,b
Pain
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
EORTC QLQ-C30 Physical Functioning
absolute change · score
Physical Functioning
-5.5 vs -0.3 Anastrozole score @ 2wkf,g,e,b
NCT02441946 · Phase 2 · registry result, not featured evidence
show 1 more dose
-3.2 vs -0.3 Anastrozole score @ 2wk
NCT02441946 · Phase 2 · registry result, not featured evidence · combination
-1.73 vs -2.94 Capecitabine scoreg,e,b
Physical functioning
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
EORTC QLQ-C30 Role Functioning
absolute change · score
Role Functioning
-11.4 vs -2.2 Anastrozole score @ 2wkf,g,e,b
NCT02441946 · Phase 2 · registry result, not featured evidence
show 1 more dose
-11.3 vs -2.2 Anastrozole score @ 2wk
NCT02441946 · Phase 2 · registry result, not featured evidence · combination
-1.09 vs -4.97 Capecitabine scoreg,e,b
Role functioning
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
EORTC QLQ-C30 Social Functioning
absolute change · score
Social Functioning
-3.5 vs -0.7 Anastrozole score @ 2wkf,g,e,b
NCT02441946 · Phase 2 · registry result, not featured evidence
show 1 more dose
-8.3 vs -0.7 Anastrozole score @ 2wk
NCT02441946 · Phase 2 · registry result, not featured evidence · combination
-0.67 vs -3.01 Capecitabine scoreg,e,b
Social functioning
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
Ki67
absolute change · percentage points
-90.52% (n=52) vs -62.78% (n=56) Anastrozole @ 2wkf,c
NCT02441946 · Phase 2 · registry result, not featured evidence
show 1 more dose
-92.86% (n=59) vs -62.78% (n=56) Anastrozole @ 2wk
NCT02441946 · Phase 2 · registry result, not featured evidence · combination
25% (n=107) vs 33% (n=94) Anastrozole + Palbociclib @ 2wkc
NCT04436744 · Phase 2 · registry result, not featured evidence · combination
ORR
responder rate · % of participants
35.2% (n=446) vs 16.1% (n=223) placeboa,b
NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
3 other source trials
13.9% (n=79) vs 13.9% (n=79) Trastuzumab + Standard of Care Chemotherapy150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
32.9% (n=79) vs 13.9% (n=79) Trastuzumab + Standard of Care Chemotherapy150 mg + 8 mg/kg + 500 mg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
26.3% (n=38) vs 10% (n=20) Fulvestrant
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
46.4% (n=444) vs 38.3% (n=222) placeboa,b
NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
12 other source trials
21% (n=347) vs 8.6% (n=174) Fulvestrant
NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
37.3% (n=169) vs 31.6% (n=171) placebo
NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
43.4% (n=145) vs 38% (n=142) placebo
NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
40.2% (n=169) vs 33.9% (n=171) placebo
NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
52.3% (n=128) vs 43.5% (n=131) placebo
NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
50% (n=112) vs 49.1% (n=108) Anastrozole + Palbociclib @ 12wk
NCT04436744 · Phase 2 · registry result, not featured evidence · combination
44.1% (n=34) vs 33.3% (n=81) Letrozole
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
55.6% (n=27) vs 39.4% (n=66) Letrozole
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
42% (n=50) vs 33.3% (n=81) Letrozole
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
55.3% (n=21) vs 39.4% (n=66) Letrozole
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
42.9% (n=84) vs 33.3% (n=81) Letrozole
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
55.4% (n=65) vs 39.4% (n=66) Letrozole
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
ORR
responder rate · % of participants
No placebo or comparator arm
19.7% (n=132)c,d,b
NCT02102490 · Phase 2
2 other source trials
53.6% (n=224)
NCT02441946 · Phase 2 · registry result, not featured evidence · combination
46.4% (n=224)
NCT02441946 · Phase 2 · registry result, not featured evidence · combination
30% (n=47)c,d,b
NCT02668666 · Phase 2 · registry result, not featured evidence
2 other source trials
47.6% (n=42)125 mg + 2.5 mg
NCT01684215 · Phase 2 · registry result, not featured evidence · combination
33.3% (n=12)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
ORR
event count · % of participants
No placebo or comparator arm
60.6% (n=33)*1000 mgf,h,e,b
NCT03099174 · Phase 1 · registry result, not featured evidence · combination · converted to % from 20 Participants as posted
show 3 more doses
19.4% (n=31)*1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination · converted to % from 6 Participants as posted
3.8% (n=26)*1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
6.7% (n=15)*1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
33.3% (n=54)*h,e,b
NCT03007979 · Phase 2 · registry result, not featured evidence · combination · converted to % from 18 Participants as posted
8 other source trials
0% (n=3) @ 24wk*100 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 0 Participants as posted
0% (n=3) @ 24wk*150 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 0 Participants as posted
6.7% (n=15) @ 24wk*150 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 1 Participants as posted
10% (n=10) @ 24wk*300 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 1 Participants as posted
0% (n=16) @ 24wk*50 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 0 Participants as posted
0% (n=6) @ 24wk*75 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 0 Participants as posted
0% (n=3) @ 24wk*75 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 0 Participants as posted
4% (n=75) @ 24wk*50 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 3 Participants as posted
Overall Survival
time to event · months
45.8 vs 37.25 placebo monthsa,b
NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
1 other source trial
26.71 vs 26.02 Fulvestrant months
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
53.9 vs 51.2 placebo monthsf,a,b
NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more dose
53.8 vs 49.8 placebo months
NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Overall Survival
time to event · months
No placebo or comparator arm
22.32 monthsc,d,b
NCT02102490 · Phase 2
4 other source trials
10.06 months
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
13.38 months
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
7.13 months
NCT02308020 · Phase 2 · registry result, not featured evidence
2.93 months
NCT02308020 · Phase 2 · registry result, not featured evidence
35.61 months*c,d,b
NCT03633331 · Phase 2 · registry result, not featured evidence · combination · converted to months from 1084 days as posted
6 other source trials
20.73 months100mg
NCT02630693 · Phase 2 · registry result, not featured evidence
21.39 months125mg
NCT02630693 · Phase 2 · registry result, not featured evidence
NA months
NCT03530696 · Phase 2 · registry result, not featured evidence
35.1 months
NCT03530696 · Phase 2 · registry result, not featured evidence · combination
37.9 months
NCT03691493 · Phase 2 · registry result, not featured evidence · combination
NA months125 mg + 2.5 mg
NCT01684215 · Phase 2 · registry result, not featured evidence · combination
PFS
time to event · months
16.4 vs 9.3 placebo monthsa,b
NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
3 other source trials
5.7 vs 5.7 Trastuzumab + Standard of Care Chemotherapy months150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
8.3 vs 5.7 Trastuzumab + Standard of Care Chemotherapy months150 mg + 8 mg/kg + 500 mg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
6.28 vs 1.95 Fulvestrant months
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
24.8 vs 14.5 placebo monthsa,b
NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
9 other source trials
9.2 vs 3.8 Fulvestrant months
NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
21.5 vs 13.9 placebo months
NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
21.6 vs 16.4 placebo months
NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
7.3 vs 9.4 Capecitabine months
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
7.5 vs 9.4 Capecitabine months
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
8 vs 10.6 Capecitabine months
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
26.1 vs 10.2 Letrozole months
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
18.1 vs 10.2 Letrozole months
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
20.2 vs 10.2 Letrozole months
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
PFS
time to event · months
No placebo or comparator arm
6 monthsc,d,b
NCT02102490 · Phase 2
8 other source trials
2.07 months
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
4.41 months
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
1.45 months
NCT02308020 · Phase 2 · registry result, not featured evidence
1.22 months
NCT02308020 · Phase 2 · registry result, not featured evidence
13.6 months1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
33.1 months1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
2.1 months1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
NA months1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
29.4 months*c,d,b
NCT03633331 · Phase 2 · registry result, not featured evidence · combination · converted to months from 895 days as posted
8 other source trials
9.33 months100mg
NCT02630693 · Phase 2 · registry result, not featured evidence
11.3 months125mg
NCT02630693 · Phase 2 · registry result, not featured evidence
9.13 months
NCT02668666 · Phase 2 · registry result, not featured evidence
8.3 months
NCT03530696 · Phase 2 · registry result, not featured evidence
16.9 months
NCT03530696 · Phase 2 · registry result, not featured evidence · combination
30.4 months
NCT03691493 · Phase 2 · registry result, not featured evidence · combination
6.53 months100mg
NCT02384239 · Phase 2 · registry result, not featured evidence
9.4 months125mg
NCT02384239 · Phase 2 · registry result, not featured evidence
Dropout rate
25.6%i
NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 28 more results
5.3%
NCT02102490 · Phase 2
31.7%Abemaciclib + Fulvestrant
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
21.2%Abemaciclib + NSAI
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
10.1%150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
6.3%150 mg + 8 mg/kg + 500 mg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
16.7%200 mg
NCT03703466 · Phase 2 · registry result, not featured evidence
8.3%200 mg
NCT03703466 · Phase 2 · registry result, not featured evidence
25%200 mg
NCT03703466 · Phase 2 · registry result, not featured evidence
—Part A Abemaciclib: HR+, HER2+ Bre
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
34.5%Part B Abemaciclib: HR+, HER2- Bre
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
33.3%Part C Abemaciclib: Surgical Resec
NCT02308020 · Phase 2 · registry result, not featured evidence
—Part D Abemaciclib: NSCLC
NCT02308020 · Phase 2 · registry result, not featured evidence
17.4%Part E Abemaciclib: Melanoma
NCT02308020 · Phase 2 · registry result, not featured evidence
—Part F: Abemaciclib HR+ Breast Can
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
6.6%Abemaciclib
NCT02441946 · Phase 2 · registry result, not featured evidence
2.7%Abemaciclib + Anastrozole
NCT02441946 · Phase 2 · registry result, not featured evidence · combination
—Abemaciclib + Anastrozole Cycle 1
NCT02441946 · Phase 2 · registry result, not featured evidence · combination
—Abemaciclib + Anastrozole Cycle 2
NCT02441946 · Phase 2 · registry result, not featured evidence · combination
—Abemaciclib Cycle 1
NCT02441946 · Phase 2 · registry result, not featured evidence
17.5%
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestonej
NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 48 more results
n/a: no completion milestone
NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
n/a: no completion milestone
NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
69.1%Palbociclib+Letrozole Australia Co
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
34%Palbociclib+Letrozole India Cohort
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
n/a: no completion milestoneCohort 1: Palbociclib Plus Exemest
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestoneCohort 2: Palbociclib Plus Fulvest
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
19.5%
NCT01864746 · Phase 3 · registry result, not featured evidence
n/a: no completion milestone
NCT02600923 · Phase 3 · registry result, not featured evidence · combination
0%
NCT02692755 · Phase 2/3 · registry result, not featured evidence · combination
1.1%
NCT03633331 · Phase 2 · registry result, not featured evidence · combination
87.5%
NCT04224272 · Phase 2 · registry result, not featured evidence · combination
1.1%125mg
NCT02630693 · Phase 2 · registry result, not featured evidence
0%100mg
NCT02630693 · Phase 2 · registry result, not featured evidence
0%
NCT02668666 · Phase 2 · registry result, not featured evidence
1.4%
NCT03644186 · Phase 2 · registry result, not featured evidence · combination
1.8%
NCT03007979 · Phase 2 · registry result, not featured evidence · combination
1.6%
NCT02536742 · Phase 2 · registry result, not featured evidence
12.5%Single Agent T-DM1
NCT03530696 · Phase 2 · registry result, not featured evidence
2.6%T-DM1 With Palbociclib
NCT03530696 · Phase 2 · registry result, not featured evidence · combination
2.8%
NCT03691493 · Phase 2 · registry result, not featured evidence · combination
3.6%
NCT04436744 · Phase 2 · registry result, not featured evidence · combination
0%125mg
NCT02384239 · Phase 2 · registry result, not featured evidence
0%100mg
NCT02384239 · Phase 2 · registry result, not featured evidence
22.1%B: Letrozole Then Letrozole + Palb
NCT02296801 · Phase 2 · registry result, not featured evidence · combination
27.5%C: Palbociclib Then Letrozole + Pa
NCT02296801 · Phase 2 · registry result, not featured evidence · combination
13.4%D: Letrozole + Palbociclib
NCT02296801 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone125 mg
NCT01684215 · Phase 2 · registry result, not featured evidence
—125 mg + 2.5 mg
NCT01684215 · Phase 2 · registry result, not featured evidence · combination
—125 mg + 2.5 mg
NCT01684215 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone100 mg
NCT01684215 · Phase 2 · registry result, not featured evidence
—Ph2P1 (Palbociclib + Letrozole)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
—Ph2P2 (Palbociclib + Letrozole)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
100%Phase 1 (Palbociclib + Letrozole)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
97.6%Phase 2 (Palbociclib + Letrozole)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone300 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
n/a: no completion milestone150 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone150 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
n/a: no completion milestone150 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
n/a: no completion milestone100 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone100 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
n/a: no completion milestone75 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
n/a: no completion milestone75 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
n/a: no completion milestone50 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone50 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone50 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
n/a: no completion milestone50 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
n/a: no completion milestone25 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone25 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
Discontinued due to AEs
—i
NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 28 more results
—
NCT02102490 · Phase 2
3.2%Abemaciclib + Fulvestrant
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
1.5%Abemaciclib + NSAI
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
—150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
—150 mg + 8 mg/kg + 500 mg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
—200 mg
NCT03703466 · Phase 2 · registry result, not featured evidence
—200 mg
NCT03703466 · Phase 2 · registry result, not featured evidence
—200 mg
NCT03703466 · Phase 2 · registry result, not featured evidence
—Part A Abemaciclib: HR+, HER2+ Bre
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
—Part B Abemaciclib: HR+, HER2- Bre
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
—Part C Abemaciclib: Surgical Resec
NCT02308020 · Phase 2 · registry result, not featured evidence
—Part D Abemaciclib: NSCLC
NCT02308020 · Phase 2 · registry result, not featured evidence
—Part E Abemaciclib: Melanoma
NCT02308020 · Phase 2 · registry result, not featured evidence
—Part F: Abemaciclib HR+ Breast Can
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
1.3%Abemaciclib
NCT02441946 · Phase 2 · registry result, not featured evidence
1.4%Abemaciclib + Anastrozole
NCT02441946 · Phase 2 · registry result, not featured evidence · combination
—Abemaciclib + Anastrozole Cycle 1
NCT02441946 · Phase 2 · registry result, not featured evidence · combination
—Abemaciclib + Anastrozole Cycle 2
NCT02441946 · Phase 2 · registry result, not featured evidence · combination
—Abemaciclib Cycle 1
NCT02441946 · Phase 2 · registry result, not featured evidence
—
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
0%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
14.3%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
14.3%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
18.2%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
12.9%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
25%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
19.2%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
20%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
7.2%j
NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 48 more results
8.9%
NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
—
NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
3.9%Palbociclib+Letrozole Australia Co
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
2%Palbociclib+Letrozole India Cohort
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
5.2%Cohort 1: Palbociclib Plus Exemest
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
2%Cohort 2: Palbociclib Plus Fulvest
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
5.2%
NCT01864746 · Phase 3 · registry result, not featured evidence
2.3%
NCT02600923 · Phase 3 · registry result, not featured evidence · combination
—
NCT02692755 · Phase 2/3 · registry result, not featured evidence · combination
—
NCT03633331 · Phase 2 · registry result, not featured evidence · combination
—
NCT04224272 · Phase 2 · registry result, not featured evidence · combination
—125mg
NCT02630693 · Phase 2 · registry result, not featured evidence
—100mg
NCT02630693 · Phase 2 · registry result, not featured evidence
—
NCT02668666 · Phase 2 · registry result, not featured evidence
—
NCT03644186 · Phase 2 · registry result, not featured evidence · combination
—
NCT03007979 · Phase 2 · registry result, not featured evidence · combination
—
NCT02536742 · Phase 2 · registry result, not featured evidence
—Single Agent T-DM1
NCT03530696 · Phase 2 · registry result, not featured evidence
—T-DM1 With Palbociclib
NCT03530696 · Phase 2 · registry result, not featured evidence · combination
—
NCT03691493 · Phase 2 · registry result, not featured evidence · combination
0.9%
NCT04436744 · Phase 2 · registry result, not featured evidence · combination
—125mg
NCT02384239 · Phase 2 · registry result, not featured evidence
—100mg
NCT02384239 · Phase 2 · registry result, not featured evidence
—B: Letrozole Then Letrozole + Palb
NCT02296801 · Phase 2 · registry result, not featured evidence · combination
—C: Palbociclib Then Letrozole + Pa
NCT02296801 · Phase 2 · registry result, not featured evidence · combination
—D: Letrozole + Palbociclib
NCT02296801 · Phase 2 · registry result, not featured evidence · combination
0%125 mg
NCT01684215 · Phase 2 · registry result, not featured evidence
—125 mg + 2.5 mg
NCT01684215 · Phase 2 · registry result, not featured evidence · combination
—125 mg + 2.5 mg
NCT01684215 · Phase 2 · registry result, not featured evidence · combination
16.7%100 mg
NCT01684215 · Phase 2 · registry result, not featured evidence
—Ph2P1 (Palbociclib + Letrozole)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
—Ph2P2 (Palbociclib + Letrozole)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
0%Phase 1 (Palbociclib + Letrozole)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
15.5%Phase 2 (Palbociclib + Letrozole)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
—300 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
—150 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
—150 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
—150 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
—100 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
—100 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
—75 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
—75 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
—50 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
—50 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
—50 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
—50 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
—25 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
—25 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
Serious AEs
29.3%i
NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 28 more results
25%
NCT02102490 · Phase 2
7.9%Abemaciclib + Fulvestrant
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
6.6%Abemaciclib + NSAI
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
19.5%150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
30.8%150 mg + 8 mg/kg + 500 mg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
12.5%200 mg
NCT03703466 · Phase 2 · registry result, not featured evidence
33.3%200 mg
NCT03703466 · Phase 2 · registry result, not featured evidence
21.7%200 mg
NCT03703466 · Phase 2 · registry result, not featured evidence
22.2%Part A Abemaciclib: HR+, HER2+ Bre
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
27.6%Part B Abemaciclib: HR+, HER2- Bre
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
33.3%Part C Abemaciclib: Surgical Resec
NCT02308020 · Phase 2 · registry result, not featured evidence
28.6%Part D Abemaciclib: NSCLC
NCT02308020 · Phase 2 · registry result, not featured evidence
17.4%Part E Abemaciclib: Melanoma
NCT02308020 · Phase 2 · registry result, not featured evidence
41.2%Part F: Abemaciclib HR+ Breast Can
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
—Abemaciclib
NCT02441946 · Phase 2 · registry result, not featured evidence
—Abemaciclib + Anastrozole
NCT02441946 · Phase 2 · registry result, not featured evidence · combination
1.4%Abemaciclib + Anastrozole Cycle 1
NCT02441946 · Phase 2 · registry result, not featured evidence · combination
7.4%Abemaciclib + Anastrozole Cycle 2
NCT02441946 · Phase 2 · registry result, not featured evidence · combination
1.3%Abemaciclib Cycle 1
NCT02441946 · Phase 2 · registry result, not featured evidence
35.9%
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
0%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
57.1%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
57.1%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
33.3%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
51.6%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
37.5%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
50%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
26.7%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
28.2%j
NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 48 more results
22.6%
NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
20.2%
NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
29.6%Palbociclib+Letrozole Australia Co
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
18%Palbociclib+Letrozole India Cohort
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
22.7%Cohort 1: Palbociclib Plus Exemest
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
14.1%Cohort 2: Palbociclib Plus Fulvest
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
10.1%
NCT01864746 · Phase 3 · registry result, not featured evidence
24.6%
NCT02600923 · Phase 3 · registry result, not featured evidence · combination
—
NCT02692755 · Phase 2/3 · registry result, not featured evidence · combination
38%
NCT03633331 · Phase 2 · registry result, not featured evidence · combination
15.7%
NCT04224272 · Phase 2 · registry result, not featured evidence · combination
13.5%125mg
NCT02630693 · Phase 2 · registry result, not featured evidence
10%100mg
NCT02630693 · Phase 2 · registry result, not featured evidence
32.7%
NCT02668666 · Phase 2 · registry result, not featured evidence
54.2%
NCT03644186 · Phase 2 · registry result, not featured evidence · combination
27.8%
NCT03007979 · Phase 2 · registry result, not featured evidence · combination
73%
NCT02536742 · Phase 2 · registry result, not featured evidence
21.4%Single Agent T-DM1
NCT03530696 · Phase 2 · registry result, not featured evidence
21.1%T-DM1 With Palbociclib
NCT03530696 · Phase 2 · registry result, not featured evidence · combination
—
NCT03691493 · Phase 2 · registry result, not featured evidence · combination
4.5%
NCT04436744 · Phase 2 · registry result, not featured evidence · combination
5.9%125mg
NCT02384239 · Phase 2 · registry result, not featured evidence
13.9%100mg
NCT02384239 · Phase 2 · registry result, not featured evidence
—B: Letrozole Then Letrozole + Palb
NCT02296801 · Phase 2 · registry result, not featured evidence · combination
—C: Palbociclib Then Letrozole + Pa
NCT02296801 · Phase 2 · registry result, not featured evidence · combination
—D: Letrozole + Palbociclib
NCT02296801 · Phase 2 · registry result, not featured evidence · combination
0%125 mg
NCT01684215 · Phase 2 · registry result, not featured evidence
9.5%125 mg + 2.5 mg
NCT01684215 · Phase 2 · registry result, not featured evidence · combination
33.3%125 mg + 2.5 mg
NCT01684215 · Phase 2 · registry result, not featured evidence · combination
0%100 mg
NCT01684215 · Phase 2 · registry result, not featured evidence
30.3%Ph2P1 (Palbociclib + Letrozole)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
24%Ph2P2 (Palbociclib + Letrozole)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
16.7%Phase 1 (Palbociclib + Letrozole)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
26.5%Phase 2 (Palbociclib + Letrozole)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
20%300 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
33.3%150 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
0%150 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
13.3%150 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
16.7%100 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
33.3%100 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
16.7%75 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
0%75 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
0%50 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
11.1%50 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
0%50 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
12%50 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
20%25 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
40%25 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
Most frequent reported AEs
i
diarrhoea 87.1% (placebo 27.8%)
neutropenia 49.7% (placebo 3.6%)
nausea 49.4% (placebo 24.7%)
NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 26 more results
diarrhoea 90.9%
nausea 67.4%
fatigue 47.7%
NCT02102490 · Phase 2
diarrhoea 28.6%
anaemia 22.2%
fatigue 20.6%
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
diarrhoea 29.9%
neutropenia 24.8%
anaemia 23.4%
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
150 mg + 8 mg/kg
diarrhoea 77.9%
fatigue 53.2%
nausea 41.6%
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
150 mg + 8 mg/kg + 500 mg
diarrhoea 79.5%
fatigue 57.7%
nausea 48.7%
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
200 mg
diarrhoea 87.5%
nausea 62.5%
anaemia 58.3%
NCT03703466 · Phase 2 · registry result, not featured evidence
200 mg
diarrhoea 91.7%
nausea 58.3%
anaemia 41.7%
NCT03703466 · Phase 2 · registry result, not featured evidence
200 mg
diarrhoea 95.7%
anaemia 47.8%
nausea 47.8%
NCT03703466 · Phase 2 · registry result, not featured evidence
diarrhoea 55.6%
fatigue 33.3%
nausea 33.3%
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
diarrhoea 77.6%
fatigue 48.3%
nausea 44.8%
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
alanine aminotransferase increased 66.7%
anaemia 44.4%
diarrhoea 44.4%
NCT02308020 · Phase 2 · registry result, not featured evidence
diarrhoea 53.6%
fatigue 39.3%
nausea 28.6%
NCT02308020 · Phase 2 · registry result, not featured evidence
abdominal pain 21.7%
diarrhoea 21.7%
neutropenia 21.7%
NCT02308020 · Phase 2 · registry result, not featured evidence
fatigue 52.9%
nausea 41.2%
diarrhoea 35.3%
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
diarrhoea 41.9%
constipation 36.5%
fatigue 25.7%
NCT02441946 · Phase 2 · registry result, not featured evidence · combination
diarrhoea 46.5%
nausea 30.9%
fatigue 28.6%
NCT02441946 · Phase 2 · registry result, not featured evidence · combination
diarrhoea 38.7%
constipation 34.7%
fatigue 22.7%
NCT02441946 · Phase 2 · registry result, not featured evidence
diarrhoea 84.6%
fatigue 43.6%
nausea 43.6%
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
1000 mg
diarrhoea 100%
decreased appetite 66.7%
vomiting 66.7%
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
1000 mg
anaemia 100%
diarrhoea 100%
aspartate aminotransferase increased 85.7%
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
1000 mg
diarrhoea 85.7%
asthenia 71.4%
neutropenia 71.4%
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
1000 mg
diarrhoea 90.9%
nausea 66.7%
neutrophil count decreased 51.5%
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
1000 mg
diarrhoea 93.5%
nausea 67.7%
neutrophil count decreased 51.6%
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
1000 mg
diarrhoea 100%
nausea 75%
asthenia 62.5%
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
1000 mg
diarrhoea 61.5%
nausea 61.5%
decreased appetite 42.3%
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
1000 mg
diarrhoea 93.3%
asthenia 60%
headache 53.3%
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
j
neutropenia 69.4% (placebo 3.6%)
arthralgia 42.1% (placebo 40.1%)
fatigue 41.2% (placebo 29.3%)
NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 42 more results
neutropenia 67%
fatigue 43.8%
nausea 36.5%
NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
neutrophil count decreased 66.7% (placebo 11.1%)
white blood cell count decreased 64.3% (placebo 9.9%)
neutropenia 44.6% (placebo 7%)
NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
neutropenia 72.4%
fatigue 65.1%
nausea 37.5%
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
neutropenia 57%
anaemia 22%
alopecia 17%
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
neutrophil count decreased 62.7%
fatigue 55.3%
hypertension 34%
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
neutrophil count decreased 63.1%
fatigue 51%
hypertension 36.9%
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
leukopenia 99.2% (placebo 69.9%)
neutropenia 95.7% (placebo 23.4%)
anemia 73.9% (placebo 30.3%)
NCT01864746 · Phase 3 · registry result, not featured evidence
neutropenia 70%
leukopenia 34.6%
anaemia 33.8%
NCT02600923 · Phase 3 · registry result, not featured evidence · combination
neutrophil count decreased 92.4%
white blood cell decreased 87%
fatigue 84.8%
NCT03633331 · Phase 2 · registry result, not featured evidence · combination
diarrhoea 92.2%
nausea 52.9%
stomatitis 41.2%
NCT04224272 · Phase 2 · registry result, not featured evidence · combination
125mg
fatigue 82%
nausea 53.9%
back pain 46.1%
NCT02630693 · Phase 2 · registry result, not featured evidence
100mg
fatigue 85.6%
nausea 52.2%
insomnia 48.9%
NCT02630693 · Phase 2 · registry result, not featured evidence
neutrophil count decreased 71.4%
fatigue 65.3%
white blood cell decreased 65.3%
NCT02668666 · Phase 2 · registry result, not featured evidence
diarrhea 65.3%
anemia 48.6%
platelet count decreased 38.9%
NCT03644186 · Phase 2 · registry result, not featured evidence · combination
white blood cell count decreased 96.3%
neutrophil count decreased 87%
anemia 79.6%
NCT03007979 · Phase 2 · registry result, not featured evidence · combination
nausea 57.1%
aspartate aminotransferase increased 50%
fatigue 50%
NCT03530696 · Phase 2 · registry result, not featured evidence
neutrophil count decreased 84.2%
platelet count decreased 76.3%
white blood cell count decreased 76.3%
NCT03530696 · Phase 2 · registry result, not featured evidence · combination
neutropenia 41.1%
neutrophil count decreased 23.2%
asthenia 22.3%
NCT04436744 · Phase 2 · registry result, not featured evidence · combination
125mg
neutrophil count decreased 26.5%
hypertension 0%
NCT02384239 · Phase 2 · registry result, not featured evidence
100mg
neutrophil count decreased 13.9%
hypertension 5.6%
NCT02384239 · Phase 2 · registry result, not featured evidence
125 mg
white blood cell count decreased 83.3%
diarrhoea 66.7%
neutrophil count decreased 66.7%
NCT01684215 · Phase 2 · registry result, not featured evidence
125 mg + 2.5 mg
neutrophil count decreased 81%
stomatitis 76.2%
white blood cell count decreased 71.4%
NCT01684215 · Phase 2 · registry result, not featured evidence · combination
125 mg + 2.5 mg
neutrophil count decreased 100%
white blood cell count decreased 100%
diarrhoea 66.7%
NCT01684215 · Phase 2 · registry result, not featured evidence · combination
100 mg
neutrophil count decreased 83.3%
white blood cell count decreased 66.7%
aspartate aminotransferase increased 33.3%
NCT01684215 · Phase 2 · registry result, not featured evidence
neutropenia 78.8%
leukopenia 48.5%
fatigue 42.4%
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
neutropenia 72%
fatigue 40%
leukopenia 40%
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
neutropenia 91.7%
fatigue 83.3%
leukopenia 66.7%
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
neutropenia 74.7%
leukopenia 43.4%
fatigue 41%
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
300 mg QD
nausea 40%
fatigue 30%
headache 30%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
150 mg QD
neutrophil count decreased 100%
anaemia 66.7%
fatigue 66.7%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
150 mg BID
abdominal pain 66.7%
ggt increased 66.7%
nausea 66.7%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
150 mg QD
nausea 40%
headache 26.7%
hypertension 26.7%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
100 mg QD
white blood cell count decreased 91.7%
neutrophil count decreased 58.3%
anaemia 41.7%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
100 mg QD
abdominal pain upper 33.3%
arthralgia 33.3%
back pain 33.3%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
75 mg BID
arthralgia 33.3%
fall 33.3%
fatigue 33.3%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
75 mg QD
hypophosphataemia 66.7%
blood alkaline phosphatase increased 33.3%
breast pain 33.3%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
50 mg BID
alt increased 50%
anaemia 50%
cough 50%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
50 mg QD
neutrophil count decreased 77.8%
white blood cell count decreased 77.8%
anaemia 66.7%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
50 mg QD
fatigue 25%
ggt increased 18.8%
arthralgia 12.5%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
50 mg QD
ggt increased 14.7%
covid-19 10.7%
ast increased 9.3%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
25 mg BID
nausea 60%
neutrophil count decreased 60%
white blood cell count decreased 60%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
25 mg QD
neutrophil count decreased 80%
white blood cell count decreased 70%
anaemia 50%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination

Notes

  1. aPopulation context differs: prior_therapy differs (unrestricted versus naive).
  2. bThe assessment timepoint is not available for both results.
  3. cPopulation comparability has not been reviewed for both studies.
  4. dTreatment context has not been resolved for both arms.
  5. ePopulation context differs: registered conditions differ.
  6. fThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  7. gTrial phases differ: Phase 2 versus Phase 3.
  8. hTrial phases differ: Phase 1 versus Phase 2.
  9. iPopulation comparability has not been reviewed for 28 of these studies.
  10. jPopulation comparability has not been reviewed for 46 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Abemaciclib

Disease Control 78.5% (n=79) vs 67.1% (n=79) Trastuzumab + Standard of Care Chemotherapy150 mg + 8 mg/kg + 500 mg
responder rate · % of participants
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
show 2 more results
74.7% (n=79) vs 67.1% (n=79) Trastuzumab + Standard of Care Chemotherapy150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
83% (n=446) vs 75.8% (n=223) placebo
NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Overall Survival Rate at 12 77.2% (n=79) vs 69.8% (n=79) Trastuzumab + Standard of Care Chemotherapy @ 52wk150 mg + 8 mg/kg + 500 mg
responder rate · % of participants
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
77.4% (n=79) vs 69.8% (n=79) Trastuzumab + Standard of Care Chemotherapy @ 52wk150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
OS Rate at 12 55.8% (n=79) vs 43% (n=79) Trastuzumab + Standard of Care Chemotherapy @ 104wk150 mg + 8 mg/kg + 500 mg
responder rate · % of participants
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
55.7% (n=79) vs 43% (n=79) Trastuzumab + Standard of Care Chemotherapy @ 104wk150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
OS 36mo 46.7% (n=79) vs 29.9% (n=79) Trastuzumab + Standard of Care Chemotherapy @ 156wk150 mg + 8 mg/kg + 500 mg
responder rate · % of participants
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
40.2% (n=79) vs 29.9% (n=79) Trastuzumab + Standard of Care Chemotherapy @ 156wk150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
BPI Total Pain 0 vs 0.31 Trastuzumab + Standard of Care Chemotherapy score150 mg + 8 mg/kg + 500 mg
absolute change · score
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
0.2 vs 0.31 Trastuzumab + Standard of Care Chemotherapy score150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
EORTC QLQ-C30 Global Health Status -2.9 vs -1.9 Trastuzumab + Standard of Care Chemotherapy score150 mg + 8 mg/kg + 500 mg
absolute change · score
Global health status
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
show 3 more results
-5.9 vs -1.9 Trastuzumab + Standard of Care Chemotherapy score150 mg + 8 mg/kg
Global health status
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
-9.5 vs -2.3 Anastrozole score @ 2wk
Global Health Status
NCT02441946 · Phase 2 · registry result, not featured evidence · combination
-7.6 vs -2.3 Anastrozole score @ 2wk
Global Health Status
NCT02441946 · Phase 2 · registry result, not featured evidence
EORTC QLQ-C30 Physical Functioning -1 vs -4.5 Trastuzumab + Standard of Care Chemotherapy score150 mg + 8 mg/kg + 500 mg
absolute change · score
Functional scale: Physical functioning
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
-4.4 vs -4.5 Trastuzumab + Standard of Care Chemotherapy score150 mg + 8 mg/kg
Functional scale: Physical functioning
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
EORTC QLQ-C30 Role Functioning -2.7 vs -8.2 Trastuzumab + Standard of Care Chemotherapy score150 mg + 8 mg/kg + 500 mg
absolute change · score
Functional scale: Role functioning
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
-5 vs -8.2 Trastuzumab + Standard of Care Chemotherapy score150 mg + 8 mg/kg
Functional scale: Role functioning
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
EORTC QLQ-C30 Emotional Functioning 2.4 vs 1.1 Trastuzumab + Standard of Care Chemotherapy score150 mg + 8 mg/kg + 500 mg
absolute change · score
Functional scale: Emotional functioning
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
-0.4 vs 1.1 Trastuzumab + Standard of Care Chemotherapy score150 mg + 8 mg/kg
Functional scale: Emotional functioning
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
EORTC QLQ-C30 Cognitive Functioning -1.8 vs -1.6 Trastuzumab + Standard of Care Chemotherapy score150 mg + 8 mg/kg + 500 mg
absolute change · score
Functional scale: Cognitive functioning
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
-1.1 vs -1.6 Trastuzumab + Standard of Care Chemotherapy score150 mg + 8 mg/kg
Functional scale: Cognitive functioning
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
EORTC QLQ-C30 Social Functioning -0.9 vs -2.4 Trastuzumab + Standard of Care Chemotherapy score150 mg + 8 mg/kg + 500 mg
absolute change · score
Functional scale: Social functioning
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
-0.9 vs -2.4 Trastuzumab + Standard of Care Chemotherapy score150 mg + 8 mg/kg
Functional scale: Social functioning
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
EORTC QLQ-C30 Fatigue 1.8 vs 4.7 Trastuzumab + Standard of Care Chemotherapy score150 mg + 8 mg/kg + 500 mg
absolute change · score
Symptom scale: Fatigue
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
7 vs 4.7 Trastuzumab + Standard of Care Chemotherapy score150 mg + 8 mg/kg
Symptom scale: Fatigue
NCT02675231 · Phase 2 · registry result, not featured evidence · combination

+ 25 further endpoints in the CSV export.

Palbociclib

Complete 1% (n=100)
responder rate · % of participants
No placebo or comparator arm
Percentage of participants with complete response
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
1.3% (n=152)
Percentage of participants with complete response
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
Partial 28% (n=100)
responder rate · % of participants
No placebo or comparator arm
Percentage of participants with partial response
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
11.8% (n=152)
Percentage of participants with partial response
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
ORR 29% (n=100)
absolute value · percentage points
No placebo or comparator arm
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
show 3 more results
13.2% (n=152)
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
24.8% (n=129)
NCT02600923 · Phase 3 · registry result, not featured evidence · combination
55% (n=47)
NCT03633331 · Phase 2 · registry result, not featured evidence · combination
EQ-5D Utility 0.698 score
absolute value · score
No placebo or comparator arm
End of Treatment (EOT)
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
EQ-5D Utility -0.147 score
absolute change · score
No placebo or comparator arm
End of Treatment (EOT)
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
EQ-5D-VAS 73.6 score
absolute value · score
No placebo or comparator arm
End of Treatment (EOT)
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
EQ-5D VAS -3.2 score
absolute change · score
No placebo or comparator arm
End of Treatment (EOT)
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
ORR 22.8% (n=206) vs 29.4% (n=187) Capecitabine
event count · % of participants
NCT02028507 · Phase 3 · registry result, not featured evidence · combination · converted to % from 47 Participants as posted
Clinical Benefit 76.2% (n=206) vs 82.4% (n=187) Capecitabine
event count · % of participants
NCT02028507 · Phase 3 · registry result, not featured evidence · combination · converted to % from 157 Participants as posted
EORTC QLQ-C30 Global Health Status 3.28 vs 1.97 Capecitabine score
absolute change · score
Global health status / QoL
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
EORTC QLQ-C30 Emotional Functioning 6.78 vs 8.67 Capecitabine score
absolute change · score
Emotional functioning
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
EORTC QLQ-C30 Cognitive Functioning -2.18 vs -2.42 Capecitabine score
absolute change · score
Cognitive functioning
NCT02028507 · Phase 3 · registry result, not featured evidence · combination

+ 61 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Abemaciclib's landscape · Palbociclib's landscape